Novel Immunological Aspects of Sirolimus as a New Targeted Therapy for COVID-19

  • Mahshid Naserifar Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
  • Hesamoddin Hosseinjani Mail Department of Clinical Pharmacy, Faculty of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran


No Abstract No Abstract No Abstract No Abstract


1. Rele S. Emerging outbreaks and epidemic threats: The practicality and limitations in the development and manufacturing of treatments for coronavirus (covid-19). Polymorphism 2020;4:45-52.
2. McIntosh K, McQuillin J, Reed SE, Gardner PS. Diagnosis of human coronavirus infection by immunofluorescence: Method and application to respiratory disease in hospitalized children. J Med Virol 1978;2(4):341-6.
3. O'Keefe BR, Giomarelli B, Barnard DL, et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family coronaviridae. J Virol 2010;84(5):2511-21.
4. Omarjee L, Janin A, Perrot F, Laviolle B, Meilhac O, Mahe G. Targeting t-cell senescence and cytokine storm with rapamycin to prevent severe progression in covid-19. Clin Immunol 2020.
5. Zhavoronkov A. Geroprotective and senoremediative strategies to reduce the comorbidity, infection rates, severity, and lethality in gerophilic and gerolavic infections. Aging (Albany NY) 2020;12(8):6492.
6. Abdel-Magid AF. Rapalogs potential as practical alternatives to rapamycin. ACS Publications; 2019.
7. Fagone P, Ciurleo R, Lombardo SD, et al. Transcriptional landscape of sars-cov-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies. Autoimmun Rev 2020:102571.
8. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-ncov/sars-cov-2. Cell Discov 2020;6(1):1-18.
9. Sargiacomo C, Sotgia F, Lisanti MP. Covid-19 and chronological aging: Senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY) 2020;12(8):6511.
10. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for covid-19 are urgently needed. Lancet 2020;395(10234):1407-9.
11. Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses sars‐cov, mers‐cov, and 2019‐ncov. J Med Virol 2020;92(5):491-4.
12. Wang C-H, Chung F-T, Lin S-M, et al. Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe h1n1 pneumonia and acute respiratory failure. Crit Care Med 2014;42(2):313-21.
How to Cite
Naserifar M, Hosseinjani H. Novel Immunological Aspects of Sirolimus as a New Targeted Therapy for COVID-19. J Pharm Care. 8(3):152-153.